Nebivolol-Induced Hepatoxicity: A Case Report.

Q3 Medicine

European journal of case reports in internal medicine Pub Date : 2024-10-01 eCollection Date: 2024-01-01 DOI:10.12890/2024_004866

Lynn Srour, Majed Ali, Karam Karam, Elias Fiani

{"title":"Nebivolol-Induced Hepatoxicity: A Case Report.","authors":"Lynn Srour, Majed Ali, Karam Karam, Elias Fiani","doi":"10.12890/2024_004866","DOIUrl":null,"url":null,"abstract":"Nebivolol is a third-generation beta-blocker known for its high selectivity for beta-1 adrenergic receptors and its unique ability to induce vasodilation via nitric oxide (NO) release. Nebivolol, despite its favourable safety profile, can lead to significant liver injury. We describe the case of a 73-year-old hypertensive patient who developed significant liver enzyme elevations following the addition of nebivolol to her treatment regimen. Comprehensive workup ruled out other causes, leading to a diagnosis of drug-induced hepatotoxicity. Discontinuation of nebivolol resulted in normalization of liver enzymes. This case underscores the importance of monitoring liver function during beta-blocker therapy, particularly with nebivolol.Learning points: Nebivolol, despite its favourable safety profile, can lead to significant liver injury.Clinicians should remain vigilant and consider routine liver function monitoring in patients prescribed nebivolol, particularly if they present with nonspecific symptoms or abnormal liver enzyme tests.Early recognition and prompt discontinuation of the offending agent are crucial in preventing severe outcomes.","PeriodicalId":11908,"journal":{"name":"European journal of case reports in internal medicine","volume":"11 11","pages":"004866"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542944/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of case reports in internal medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12890/2024_004866","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Nebivolol is a third-generation beta-blocker known for its high selectivity for beta-1 adrenergic receptors and its unique ability to induce vasodilation via nitric oxide (NO) release. Nebivolol, despite its favourable safety profile, can lead to significant liver injury. We describe the case of a 73-year-old hypertensive patient who developed significant liver enzyme elevations following the addition of nebivolol to her treatment regimen. Comprehensive workup ruled out other causes, leading to a diagnosis of drug-induced hepatotoxicity. Discontinuation of nebivolol resulted in normalization of liver enzymes. This case underscores the importance of monitoring liver function during beta-blocker therapy, particularly with nebivolol.

Learning points: Nebivolol, despite its favourable safety profile, can lead to significant liver injury.Clinicians should remain vigilant and consider routine liver function monitoring in patients prescribed nebivolol, particularly if they present with nonspecific symptoms or abnormal liver enzyme tests.Early recognition and prompt discontinuation of the offending agent are crucial in preventing severe outcomes.

查看原文本刊更多论文

奈必洛尔诱发的肝中毒：病例报告

奈必洛尔是第三代β-受体阻滞剂，因其对β-1肾上腺素能受体的高选择性和通过一氧化氮（NO）释放诱导血管扩张的独特能力而闻名。尽管奈必洛尔具有良好的安全性，但它可能导致严重的肝损伤。我们描述了一例 73 岁高血压患者的病例，她在治疗方案中加入奈必洛尔后出现了明显的肝酶升高。综合检查排除了其他病因，最终诊断为药物性肝中毒。停用奈必洛尔后，肝酶恢复正常。本病例强调了在β-受体阻滞剂治疗期间监测肝功能的重要性，尤其是使用奈必洛尔时：临床医生应保持警惕，考虑对服用奈必洛尔的患者进行常规肝功能监测，尤其是当患者出现非特异性症状或肝酶检测异常时。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European journal of case reports in internal medicine

CiteScore

2.10

自引率

0.00%

发文量

166

审稿时长

8 weeks

期刊介绍： The European Journal of Case Reports in Internal Medicine is an official journal of the European Federation of Internal Medicine (EFIM), representing 35 national societies from 33 European countries. The Journal''s mission is to promote the best medical practice and innovation in the field of acute and general medicine. It also provides a forum for internal medicine doctors where they can share new approaches with the aim of improving diagnostic and clinical skills in this field. EJCRIM welcomes high-quality case reports describing unusual or complex cases that an internist may encounter in everyday practice. The cases should either demonstrate the appropriateness of a diagnostic/therapeutic approach, describe a new procedure or maneuver, or show unusual manifestations of a disease or unexpected reactions. The Journal only accepts and publishes those case reports whose learning points provide new insight and/or contribute to advancing medical knowledge both in terms of diagnostics and therapeutic approaches. Case reports of medical errors, therefore, are also welcome as long as they provide innovative measures on how to prevent them in the current practice (Instructive Errors). The Journal may also consider brief and reasoned reports on issues relevant to the practice of Internal Medicine, as well as Abstracts submitted to the scientific meetings of acknowledged medical societies.